July, 2019
MPNRF Under the Microscope
|
|
"Cancer is a Thief" - Ruben Mesa, M.D., FACP
Some may wonder what drives someone to become a Cancer researcher. In this video Dr. Ruben Mesa speaks movingly of his personal and professional motivations as a Cancer Center Director, renowned MPN researcher and human being who has experienced personal loss. Thank you Dr. Mesa for sharing your "why".
|
|
 |
MPN Research Consortium Launches New Website
The Myeloproliferative Neoplasms Research Consortium (MPN-RC), funded by the National Cancer Institute (NCI), has launched a new website showcasing their innovative laboratory and clinical research focused on finding a cure for Myelofibrosis. Click below to explore their site and see the collaboration that is ongoing among researchers globally.
|
|
|
|
The MPN Familial Study
Does more than one person in your family have an MPN? Several studies have described families with predisposition towards a diagnosis of an MPN. In an effort to get to the bottom of this, the Fleischman Lab, headed by Dr. Angela Fleischman, MD. PhD. in Irvine, CA is studying familial clusters of PV, ET and MF. To learn more or get involved send an email to
[email protected]
|
|
|
|
Patient Focused Drug Development Meeting
|
|
|
Mon, Sep 16, 2019 9:00 AM ED
Externally-led Patient Focused Drug Development mee
ting for PV, ET & MF
College Park Marriott Hotel and Conference Center, Hyattsville, MD
|
|
The FDA has accepted the Myeloproliferative Neoplasms (MPN) community for an externally-led PFDD meeting this September for people living with PV, ET, and MF. The patient perspective is critical in helping the FDA understand the context in which regulatory decisions are made for new drugs. PFDD meetings give FDA and other key stakeholders an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the impact the disease has on their daily lives. This input can inform FDA’s decisions and oversight both during drug development & during our review of a marketing application.
|
|
Today, July 31, is the
last day to participate!
If you're living with PV, ET or MF we invite you to take a quick two question phone survey of which will be presented to the FDA during the Externally-led Patient Focused Drug Development meeting
.
What has been the most difficult part of living with this disease for you?
How has your diagnosis impacted the fulfillment of your life goals?
The number to dial is (877) 851-5399
|
|
Drug
:
Rigosertib
Company
:
Onconova Therapeutics, Inc.
Study name
:
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Enrolling
: Patients with confirmed diagnosis of PMF, post-PV, or post-ET, who are anemic or RBC-transfusion dependent, and who have an ECOG performance standard of less than 2.
To learn more click
here
.
|
|
Drug:
CPI-0610
Company: Constellation Pharmaceuticals
Study name:
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Enrolling: Patients with a confirmed diagnosis of MF, a peripheral blood count blast of less than 10%, and an ECOG performance standard of less than 2.
To learn more click
here
.
|
|
The Many Ways You Can Help
With your support, the MPN Research Foundation has provided over $13 million in grants to fund 63 researchers working to better the lives of patients with MF, ET, and PV. By donating, you can have a hand in the future of treatments and the development of a cure!
|
|
There are several patient and caregiver events coming up in the month of August! Head over to our
MPN Community Calendar
on MPNRF's website and check out the many educational meetings and webinars taking place!
|
|
|
|
|
|
Do your shopping at
smile.amazon.com and a percentage of what you spend will be donated to charity. Make sure to select the MPN Research Foundation as your institution of choice!
|
|
|
|
|
|
|
